TRI-SPRINTEC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tri-sprintec, and when can generic versions of Tri-sprintec launch?
Tri-sprintec is a drug marketed by Barr and is included in one NDA.
The generic ingredient in TRI-SPRINTEC is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRI-SPRINTEC?
- What are the global sales for TRI-SPRINTEC?
- What is Average Wholesale Price for TRI-SPRINTEC?
Summary for TRI-SPRINTEC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Clinical Trials: | 2 |
| Patent Applications: | 8 |
| Drug Prices: | Drug price information for TRI-SPRINTEC |
| Drug Sales Revenues: | Drug sales revenues for TRI-SPRINTEC |
| DailyMed Link: | TRI-SPRINTEC at DailyMed |
See drug prices for TRI-SPRINTEC
Recent Clinical Trials for TRI-SPRINTEC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Pennsylvania | Phase 1 |
| Society of Family Planning | Phase 1 |
| American Heart Association | Phase 4 |
US Patents and Regulatory Information for TRI-SPRINTEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr | TRI-SPRINTEC | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 075808-001 | Dec 29, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
